- Pfizer said two jabs failed to produce the expected immunity in babies and preschoolers
- A preliminary analysis found 2- to 4-year-olds’ immune response wasn’t as strong as expected to the lose-dose jabs for younger children
- If three doses proves successful, Pfizer and its partner BioNTech said they would apply for emergency authorization sometime in the first half of 2022
- Third shot will come at least two months after the youngsters’ second dose
- The setback comes as COVID cases are spiking and the Omicron variant is taking hold in the US
Pfizer said Friday it’s going to test three doses of its COVID vaccine in young children under five years old, after two jabs failed to produce the expected immunity in babies and preschoolers.
Two doses didn’t appear strong enough in some of the kids, the company said, saying that a preliminary analysis found 2- to 4-year-olds’ immune response wasn’t as strong as expected to the lose-dose jabs for younger children.
If three doses proves successful, Pfizer and its partner BioNTech said they would apply for emergency authorization sometime in the first half of 2022.
The company already has a ‘kid-sized’ vaccine for 5- to 11-year-olds, which is one-third the dosage given to adults and children 12 and older.
AC
Views: